このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

エスケタミンの有効性と安全性を評価する大うつ病性障害の症状軽減を目的とした研究 (AVENUE)

2026年11月2日 更新者:Janssen Research & Development, LLC

二重盲検ランダム化比較試験:自殺念慮または行動を伴う思春期参加者における大うつ病性障害の症状の迅速な軽減を目的とした、包括的標準治療に加えて経鼻エスケタミン84mgを投与する場合の有効性および安全性の評価(向精神薬プラセボ対照試験)

The purpose of this study is to evaluate how well JNJ-54135419 works (efficacy) in addition to comprehensive standard of care (SoC) in rapidly reducing the symptoms of major depressive disorder (MDD, a mental disorder characterized by a persistent feeling of sadness and loss of interest in activities) as compared with psychoactive placebo (does not contain JNJ-54135419) plus SoC in adolescent participants with acute suicidal ideation or behavior.

調査の概要

研究の種類

介入

入学 (推定)

258

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35294
        • 募集
        • University of Alabama at Birmingham
    • Connecticut
      • New Haven、Connecticut、アメリカ、06511
        • 募集
        • Yale Child Study Center
    • District of Columbia
      • Washington D.C.、District of Columbia、アメリカ、20010
        • 募集
        • Children's National Medical Center
    • Georgia
      • Atlanta、Georgia、アメリカ、30338
        • 募集
        • Peachford Hospital-Atlanta Behavioral Research
    • Illinois
      • Evanston、Illinois、アメリカ、60201
        • 募集
        • Endeavor Health Evanston Hospital
    • Maryland
      • Baltimore、Maryland、アメリカ、21287
        • 募集
        • Johns Hopkins University
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02445
        • 募集
        • Boston Childrens Hospital
    • Minnesota
      • Rochester、Minnesota、アメリカ、55905
        • 募集
        • Mayo Clinic
    • North Carolina
      • Chapel Hill、North Carolina、アメリカ、27514
        • 募集
        • University of North Carolina at Chapel Hill
    • Ohio
      • Cincinnati、Ohio、アメリカ、45219
        • 募集
        • University of Cincinnati
    • Rhode Island
      • East Providence、Rhode Island、アメリカ、02915
        • 募集
        • Bradley Hospital
    • Texas
      • Houston、Texas、アメリカ、77021
        • 募集
        • John S Dunn Behavioral Sciences Center at UTHealth Houston
      • Acireale、イタリア、95024
        • 募集
        • Presidio Ospedaliero Santa Marta e Santa Venera
      • Cagliari、イタリア、09134
        • 募集
        • Azienda Ospedaliera G. Brotzu
      • Florence、イタリア、50134
        • 募集
        • AOU Meyer
      • Foggia、イタリア、71122
        • 募集
        • Azienda Ospedaliera Universitaria Policlinico Riuniti di Foggia
      • Genova、イタリア、16147
        • 募集
        • G.Gaslini Institute
      • Merano、イタリア、39012
        • 募集
        • Ospedale di Merano
      • Naples、イタリア、80131
        • 募集
        • Azienda Ospedaliera Universitaria Federico II
      • Sassari、イタリア、07100
        • 募集
        • Azienda Ospedaliero Universitaria di Sassari
      • Barcelona、スペイン、08036
        • 募集
        • Hosp. Clinic de Barcelona
      • Barcelona、スペイン、08035
        • 募集
        • Hosp Univ Vall D Hebron
      • Esplugues de Llobregat、スペイン、08950
        • 募集
        • Hosp. Sant Joan de Deu
      • Madrid、スペイン、28046
        • 募集
        • Hosp. Univ. La Paz
      • Madrid、スペイン、28009
        • 募集
        • Hosp. Gral. Univ. Gregorio Maranon
      • Manresa、スペイン、08243
        • 募集
        • Fundacio Althaia Xarxa Assistencial Universitaria de Manresa
      • Oviedo、スペイン、33011
        • 募集
        • Hosp. Univ. Central de Asturias
      • Pamplona、スペイン、31008
        • 募集
        • Clinica Univ. de Navarra
      • Sabadell、スペイン、08208
        • 募集
        • Hosp.Univ.Parc Tauli
      • Santander、スペイン、39008
        • 募集
        • Hosp. Univ. Marques de Valdecilla
      • Budapest、ハンガリー、1021
        • 募集
        • Vadaskert Gyermek es Ifjusagpszichiatriai Korhaz es Szakambulancia
      • Debrecen、ハンガリー、4031
        • 募集
        • Debreceni Egyetem Klinikai Kozpont
      • Győr、ハンガリー、9023
        • 募集
        • Petz Aladar Megyei Oktato Korhaz
      • Szeged、ハンガリー、6720
        • 募集
        • Szegedi Tudomanyegyetem
      • Criciúma、ブラジル、88811 000
        • 募集
        • Sociedade Literaria e Caritativa Santo Agostinho Hospital Sao Jose
      • Natal、ブラジル、59012 300
        • 募集
        • Universidade Federal do Rio Grande do Norte Hospital Universitario Onofre Lopes
      • Salvador、ブラジル、40170 108
        • 募集
        • Instituto Apice
      • São Bernardo do Campo、ブラジル、09726 150
        • 募集
        • Centro Integrado Facili
      • São Paulo、ブラジル、01 227 200
        • 募集
        • Instituto de Pesquisa Pensi Sandra Mutarelli Setubal
      • São Paulo、ブラジル、05403-900
        • 募集
        • Hospital Das Clinicas Da Faculdade De Medicina Da USP
      • Bucharest、ルーマニア、041914
        • 募集
        • Spitalul Clinic de Psihiatrie Prof Dr Alexandru Obregia
      • Cluj-Napoca、ルーマニア、400347
        • 募集
        • Spitalul Clinic de Urgenta pentru Copii Cluj Napoca
      • Sibiu、ルーマニア、550082
        • 募集
        • Spitalul Clinic De Psihiatrie Doctor Gheorghe Preda
      • Timișoara、ルーマニア、300329
        • 募集
        • Spitalul Clinic de Urgenta pentru Copii 'Louis Turcanu' Timisoara
      • New Taipei City、台湾、251
        • 募集
        • Mackay Memorial Hospital Tamsui Branch
      • Taipei、台湾、114
        • 募集
        • Tri-Service General Hospital
      • Taipei、台湾、100
        • 募集
        • National Taiwan University Hospital
      • Taipei、台湾、112
        • 募集
        • Taipei Veterans General Hospital
      • Taipei、台湾、110
        • 募集
        • Taipei Medical University Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

12年~17年 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Must meet diagnostic and statistical manual of mental disorders (5th edition) (DSM-5) diagnostic criteria for major depressive disorder (MDD) based upon clinical assessment and confirmed by the mini-international neuropsychiatric interview for children and adolescents (MINI-KID)
  • Must have a clinical global impression - severity of suicidality - revised (CGI-SS-R) score of "Markedly" or greater (that is, greater than or equal to [>=] 4) at both screening and baseline (predose) visits
  • Must have a children's depression rating scale - revised (CDRS-R) total score >= 58 at baseline (predose)
  • In the physician's opinion, acute psychiatric hospitalization is clinically warranted due to subject's acute suicidality
  • Must be medically stable based on physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening

Exclusion Criteria:

  • Participant has a current DSM-5 diagnosis of bipolar (or related disorders), intellectual disability, autism spectrum disorder, conduct disorder, oppositional defiant disorder
  • Participant currently meets DSM-5 criteria for borderline personality disorder
  • Participant has a current or prior DSM-5 diagnosis of a psychotic disorder, or MDD with psychosis
  • Participant has a history of seizure disorder
  • Participant has known allergies, hypersensitivity, intolerance or contraindications to midazolam, esketamine or ketamine, or their excipients

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Intranasal Esketamine + Oral Placebo

Participants will receive intranasal esketamine 84 milligrams (mg) along with oral placebo solution twice weekly for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25). On Day 4 a decrease to intranasal esketamine 56 mg (in a blinded fashion per investigator's judgment) is permitted. Thereafter, dose may be flexed between 56 mg and 84 mg during the treatment period.

Esketamine will be administered as intranasal solution.

他の名前:
  • JNJ-54135419

Placebo will be administered as oral solution.

プラセボコンパレーター:Intranasal Placebo + Oral Midazolam

Participants will receive oral midazolam (0.0625 milligrams per kilograms [mg/kg]) and intranasal placebo twice weekly for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25). On Day 4 a sham decrease to esketamine 56 mg dose (in a blinded fashion per investigator's judgment) is permitted. Thereafter, sham dose may be flexed between 56 mg and 84 mg during the treatment period.

Midazolam will be administered as oral solution.

Intranasal placebo will be administered as nasal solution.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change from Baseline in Depressive Symptoms Measured by Children's Depression Rating Scale - Revised (CDRS-R) Total Score at 24 Hours Post First Dose
時間枠:Baseline (pre-dose on Day 1) and 24 hours post first dose (i.e., Day 2)

The CDRS-R is a 17-item, clinician-reported outcome measure of children's depressive symptom severity. Out of the 17-item, 3 items were non-verbal behavior (listless speech, hypoactivity, and depressed affect) rated on a 5 point scale from 1 (no depression) to 5 (severe depression) and 14 items were rated on a 7-point scale from 1 (no depression) to 7 (severe depression), where higher score indicated more severe depression. The CDRS-R total score was the sum of the 17-tems score and it ranged from 17 (normal) to 113 (severe depression). Higher score indicated more severe depression and worse outcome.

Baseline (pre-dose on Day 1) and 24 hours post first dose (i.e., Day 2)

二次結果の測定

結果測定
メジャーの説明
時間枠
Change from Baseline in CDRS-R Total Score at Day 25
時間枠:Baseline (predose on Day 1) and Day 25 (4 hours post dose)

The CDRS-R is a 17-item, clinician-reported outcome measure of children's depressive symptom severity. Out of the 17-item, 3 items were non-verbal behavior (listless speech, hypoactivity, and depressed affect) rated on a 5-point scale from 1 (no depression) to 5 (severe depression) and 14 items were rated on a 7-point scale from 1 (no depression) to 7 (severe depression), where higher score indicated more severe depression. The CDRS-R total score was the sum of the 17-tems score and it ranged from 17 (normal) to 113 (severe depression). Higher score indicated more severe depression and worse outcome.

Baseline (predose on Day 1) and Day 25 (4 hours post dose)
Change from Baseline in Clinical Global Impression - Severity of Suicidality - Revised (CGI-SS-R) Score at 24 Hours Post First Dose
時間枠:Baseline (pre-dose on Day 1) and 24 hours post first dose (i.e., Day 2)

The CGI-SS-R is a single item clinician-rated measure of the severity of participants' suicidality. The CGI-SS-R asks clinicians to rate the severity of a participant's suicidality using a 7-point scale that ranges from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal patients). Higher scores indicate greater severity.

Baseline (pre-dose on Day 1) and 24 hours post first dose (i.e., Day 2)
Change From Baseline in Symptoms of MDD During the Double-Blind (DB) Treatment Phase as Measured by CDRS-R Total Score
時間枠:From Baseline up to Day 25

The CDRS-R is a 17-item, clinician-reported outcome measure of children's depressive symptom severity. Out of the 17-item, 3 items were non-verbal behavior (listless speech, hypoactivity, and depressed affect) rated on a 5-point scale from 1 (no depression) to 5 (severe depression) and 14 items were rated on a 7-point scale from 1 (no depression) to 7 (severe depression), where higher score indicated more severe depression. The CDRS-R total score was the sum of the 17-tems score and it ranged from 17 (normal) to 113 (severe depression). Higher score indicated more severe depression and worse outcome.

From Baseline up to Day 25
Percentage of Participants with Remission of Depressive Symptoms During the DB Treatment Phase
時間枠:Up to Day 25

Remission of depressive symptoms is defined as a CDRS-R total score of both less than or equal to (<=) 28 and <= 34 during the DB treatment phase. The CDRS-R is a 17-item, clinician-reported outcome measure of children's depressive symptom severity. Out of the 17-item, 3 items were non-verbal behavior (listless speech, hypoactivity, and depressed affect) rated on a 5 point scale from 1 (no depression) to 5 (severe depression) and 14 items were rated on a 7-point scale from 1 (no depression) to 7 (severe depression), where higher score indicated more severe depression. The CDRS-R total score was the sum of the 17-tems score and it ranged from 17 (normal) to 113 (severe depression). Higher score indicated more severe depression and worse outcome.

Up to Day 25
Percentage of Responders on Depressive Symptoms During the DB Treatment Phase
時間枠:Up to Day 25

Responders on depressive symptoms is defined as >= 50 percent (%) improvement in CDRS-R total score from baseline during the DB treatment phase. The CDRS-R is a 17-item, clinician-reported outcome measure of children's depressive symptom severity. Out of the 17-item, 3 items were non-verbal behavior (listless speech, hypoactivity, and depressed affect) rated on a 5 point scale from 1 (no depression) to 5 (severe depression) and 14 items were rated on a 7-point scale from 1 (no depression) to 7 (severe depression), where higher score indicated more severe depression. The CDRS-R total score was the sum of the 17-tems score and it ranged from 17 (normal) to 113 (severe depression). Higher score indicated more severe depression and worse outcome.

Up to Day 25
Percentage of Participants with Resolution of Suicidality During the DB Treatment Phase
時間枠:Up to Day 25

Participants with resolution of suicidality is defined as a score of 0 (normal, not at all suicidal) or 1 (questionably suicidal) on CGI SS-R, during the DB treatment phase. The CGI-SS-R asks clinicians to rate the severity of a participant's suicidality using a 7-point scale that ranges from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal patients). Higher score indicate greater severity.

Up to Day 25
Change From Baseline in Severity of Suicidality As Measured by Clinical Global Impression - Severity of Suicidality - Revised (CGI-SS-R) During the DB Treatment Phase
時間枠:From Baseline up to Day 25

The CGI-SS-R is a single item clinician-rated measure of the severity of participants' suicidality. The CGI-SS-R asks clinicians to rate the severity of a participant's suicidality using a 7-point scale that ranges from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal patients). Higher score indicate greater severity.

From Baseline up to Day 25
Change From Baseline in Clinician-Reported Frequency of Suicidal Thinking (FoST-ClinRO) During the DB Treatment Phase
時間枠:From Baseline up to Day 25

FoST-ClinRO is a clinician-rated measure used to assess a participant's frequency of suicidal thinking assessed during the DB treatment phase. The measure uses a 6-point Likert scale that ranges from 0=Never, to 5=All of the time to assess suicidal thinking frequency, where higher scores indicate a more severe condition.

From Baseline up to Day 25
Change from baseline in Patient-Reported Frequency of Suicidal Thinking (FoST-PRO) During the DB Treatment Phase
時間枠:From Baseline up to Day 25

FoST-PRO is a single item participant reported measure of the frequency of one's suicidal thinking right now. The single item asks participants to rate the frequency with which they have suicidal thoughts (0 = I have no suicidal thoughts, 1 = I have suicidal thoughts a little of the time, 2 = I have suicidal thoughts some of the time, 3 = I have suicidal thoughts most of the time, and 4 = I have suicidal thoughts all of the time). Higher scores indicate greater severity.

From Baseline up to Day 25
Change from Baseline in Patient Health Questionnaire, 9-item Modified for Adolescents (PHQ-A) Total Score During the DB Treatment Phase
時間枠:From Baseline up to Day 25

The PHQ-A is a modified version of the PHQ-9 scale, specifically designed to measure depressive symptom severity in adolescents. A 10-item version of the PHQ-A will be used in this study; the first 9 items assess depressive symptoms. Adolescents use a 4 point Likert scale to rate the severity of their symptoms over the past 2 weeks (range: 0 = not at all to 3 = nearly every day). The PHQ-A total score is the sum of all item responses. The total score can be used to classify adolescents based on the severity of their depressive symptoms: 0-4 (no or minimal depression), 5-9 (mild depression), 10-14 (moderate depression), 15-19 (moderately severe depression), and 20-27 (severe depression). The tenth PHQ-A item measures the degree to which adolescents experience functional difficulties due to their depressive symptoms. Higher scores indicate greater depressive symptoms.

From Baseline up to Day 25
Change From Baseline in KIDSCREEN-10 Total Score During the DB Treatment Phase
時間枠:From Baseline up to Day 25

KIDSCREEN-10 is a global patient-reported outcome (PRO) measure of well-being and health-related quality of life in children and adolescents aged 8-18 years. It includes 10 items that measure the subjective health and psychological, mental and social well-being experiences of children and adolescents over the past week. The scores for the 10 items are summed to produce a total score. This total score can then be transformed into a T-score or percentile rank, based on normative data, to facilitate interpretation. The higher the total score, the better the reported health-related quality of life (HRQoL).

From Baseline up to Day 25
Change from Baseline in Patient Global Impression of Severity (PGI-S) Depressive Symptoms at 24 Hours Post First Dose
時間枠:Baseline (predose on Day 1) and 24 hours post first dose (i.e., Day 2)

The PGI-S is a single PRO item that captures one's perceptions of the severity of his/her depressive symptoms over the past 24 hours. Participants will be asked to rate their disease severity using the following 5-point scale: 1 = None, 2 = Mild, 3 = Moderate, 4 = Severe, and 5 = Very severe. Higher scores indicate greater disease severity.

Baseline (predose on Day 1) and 24 hours post first dose (i.e., Day 2)
Change from Baseline in Clinical Global Impression - Severity Scale (CGI-S) Depressive Symptoms at 24 Hours Post First Dose
時間枠:Baseline (pre-dose on Day 1) and 24 hours post first dose (i.e., Day 2)

The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that considers all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S will be used to rate the overall severity of illness on a scale of 1 to 7. Considering total clinical experience with the depression population, a participant is assessed on severity of illness at the time of rating according to the following scale: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. Higher scores indicate greater severity.

Baseline (pre-dose on Day 1) and 24 hours post first dose (i.e., Day 2)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年1月8日

一次修了 (推定)

2031年4月9日

研究の完了 (推定)

2031年9月15日

試験登録日

最初に提出

2025年11月11日

QC基準を満たした最初の提出物

2025年11月11日

最初の投稿 (実際)

2025年11月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月3日

QC基準を満たした最後の更新が送信されました

2026年11月2日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 54135419SUI3003
  • 54135419SUI3003 (その他の識別子:Janssen Research & Development, LLC)
  • 2024-518615-19-00 (レジストリ識別子:EUCT number)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する